PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

Weekly companies-for-sale update, featuring two newly announced deals in fire safety and drug development; KKR announces ...

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...

Bain and Kohlberg are leading an investment round in PCI Pharma Services, valuing it at $10 billion, as AI accelerates drug ...

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.